EC Number   |
Application |
Reference |
|---|
    1.6.5.2 | analysis |
development of a functional affinity-based small-molecule probe composed of a potent small-molecule NQO1 inhibitor 4-hydroxy-3-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-2H-1-benzopyran-2-one as the recognition group, a linker and the fluorophores group FITC. The probe exhibits good inhibitory activity of NQO1 and can be used to label the protein in A549 cells at the micromolar level |
744842 |
| 1.6.5.2 | analysis |
method to measure enzyme inhibition in intact cells based on the resorufin reductase activity of enzyme. Values for 50% inhibition of enzyme by several reported in vivo inhibitors is at least three orders of magnitude higher for intact cells than for cell lysates |
673789 |
| 1.6.5.2 | analysis |
the enzyme is a catalyst for 1,4-dihydronicotinamide adenine dinucleotide-dependent amperometric biosensors and biofuel cells. For NADH detection, a linear range between 0.005 mM and 1 mM, a limit of detection of 0.003 mM, and a high sensitivity can be reached |
721281 |
| 1.6.5.2 | biotechnology |
the flavoprotein WrbA from Escherichia coli represents a new family of multimeric flavodoxin-like proteins implicated in cell protection against oxidative stress, WrbA has NAD(P)H: quinone reductase activity, forms multimers and binds FMN only weakly |
688795 |
| 1.6.5.2 | degradation |
TcpB is acting as a quinone reductase for 6-chlorohydroxyquinone reduction during 2,4,6-trichlorophenol degradation, a toxic pollutant |
692844 |
| 1.6.5.2 | drug development |
ability of ketoconazole and itraconazole to induce NQO1 gene expression at the transcriptional level through an aryl hydrocarbon receptor-dependent mechanism |
691592 |
| 1.6.5.2 | drug development |
cytoprotective effect of bromocriptine involving PI3K- and Nrf2-mediated upregulation of the antioxidant enzyme NQO1, which may be a therapeutic strategy to protect cells from oxidative damage in Parkinsons disease |
694566 |
| 1.6.5.2 | drug development |
design of novel lavendamycin analogues with enhanced, selective, and potent antitumor activity |
688277 |
| 1.6.5.2 | drug development |
greater induction activities of the phase II enzyme quinone reductase associated with stilbenoids serve as a useful starting point for the design of improved chemopreventive agents |
692171 |
| 1.6.5.2 | drug development |
in vitro, almond skin polyphenols act as antioxidants and induce quinone reductase activity, but these actions are dependent upon their dose, method of extraction, and interaction with antioxidant vitamins |
692722 |
